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Aging populations experience a decline in adaptive immune system function also known
as immunosenesence. Protein nutrition has been shown to stimulate and strengthen
the immune system, and such approaches are needed for this growing segment of
the population. A controlled, randomized, double blind pilot study was conducted to
compare two different protein sources (soy and dairy) as nutritional supplementation to
enhance vaccine response. Our objective was to examine the immune stimulating effects
of dairy protein subjected to ultraviolet radiation (UV-C) radiation treatment process
instead of pasteurization. Participants were 21 healthy individuals over 60 years of age
who consumed 6g of the dairy protein or a comparison, soy isoflavone protein, twice a
day for 8 weeks. DTaP vaccine administered at week 4. Non-parametric t-tests revealed a
significant increase in Tetanus antibodies in the dairy group compared to the soy group at
week 8. These findings suggest additional benefits of UV-C treated unheated dairy protein
as a solution to counteract immunosenescence, but warrant further study in elderly and
other populations that might benefit from immune system stimulation.
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INTRODUCTION
Immunization is an effective strategy against infectious disease; however, immunological function
often falters as humans age (1, 2). Data indicate that 90% of deaths from infectious disease in the
elderly are vaccine-preventable (3). Immunosenescence is a condition in which the immune system
decreases in its response to pathogens. Likewise, immunosenescence often decreases the efficacy of
vaccines in the elderly, increasing this particular demographics’ susceptibility to severe infection
(4). Several reports have demonstrated that older individuals lack robust response to conventional
vaccines (4–6). For example, antibody responses to influenza and tick-borne encephalitis vaccine
were impaired in the elderly (5). Such data suggest that immunosenescence is an important
issue to overcome in the development of effective vaccine response in aging populations and for
improving immune function in general. Taken together with the increased proportions of persons
living beyond 65 years of age (7), these data indicate a need for alternative strategies to decrease
immunosenescence, and thereby enhance immune responses in aging populations.
Protein-energy malnutrition has been linked with impaired immune function in the elderly
(2, 8). Protein supplementation can enhance the immune system response, and there is evidence
that dairy protein may yield additional benefits over plant-based protein sources, (9). While these
data are promising, more research is needed to confirm the immune benefits of dairy protein over
non-dairy sources, and also the impact of the various sources of dairy protein.
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While raw dairy has been associated with notable risks caused
by ingestion of milk borne pathogens, it is also associated with
several health benefits including decreased incidence of asthma,
allergies and respiratory infections (10). This may suggest some
immune benefits of dairy proteins are lost upon heat processing.
Now, non-thermal processing technologies can render milk safe
by reducingmicroorganisms to a similar level asmilk subjected to
a thermal pasteurization process, while at the same time aiming
to retain the bioactivity of the dairy proteins. TruActivTM NF is a
protein product isolated from bovine milk that is manufactured
in the U.S. It uses ultraviolet radiation (UV-C) treatment of
a raw nonfat milk to destroy or eliminate the most resistant
microorganisms of public health concern, based on previously
described enumeration tests (11–14). Hence, UV-C treatment of
raw milk allows for a method other than heat pasteurization to
destroy or eliminate the most resistant microorganisms of public
health concern, as discussed in the Food, Drug, and Cosmetic
Act (FD&C, 2013) (15). Several studies have concluded UV-
C treatment to be an effective technology to reduce microbial
populations in milk and other foods (16–18). It is yet unknown
however, whether UV-C treated milk protein has immunological
benefits.
More research is needed to understand the general benefits
of dairy products on immune stimulation as a potential strategy
to counteract immunosenescence in the elderly. The goal of
the present study is to evaluate the impact of dairy protein
supplementation on vaccine response by using a novel and
safe unheated dairy protein source. We examined DTaP vaccine
response in two elderly group’s supplemented with either the
novel dairy protein or soy protein. The study objectives were
to (1) characterize and quantify DTaP-specific antibodies from
the peripheral blood of participants, and (2) determine how




A controlled, randomized, double blind pilot study was
conducted that measured DTaP vaccine response in two groups
of elderly volunteers (n = 21) supplemented with either the
dairy or soy protein. Healthy volunteers were recruited from
retirement centers and long-term care facilities in Northern
California. The DTaP vaccine was selected since Pertussis is
of growing concern in the elderly; however, it is not currently
required for admission to these facilities.
Inclusion criteria included participants be more than 60
years of age. Volunteers underwent a physical examination
and health assessment by a physician to ensure the absence of
exclusion criteria which were regular consumption of greater
than one unit of milk and/or milk products (milk, yogurt,
fresh cheese, etc.) a day at the time of enrollment, known
milk allergy, food faddism, other non-traditional diet, prolonged
consumption of dairy supplements (greater than one daily
during the previous four weeks), use of tobacco products in
the previous 10 years, underlying neoplasia or immunological
disease, including hypergammaglobunemia, renal disease or
failure, use of steroids or immunosuppressive drugs in the
previous eight weeks, reduced physical activity (New York Heart
Association classes III-IV). Having received a DTaP vaccine
within the last 5 years was an exclusion criteria for the study,
but patient records were incomplete for many volunteers on this
aspect. Therefore, volunteers with an initial Tetanus antibody
level above 3 IU/mL were excluded from the study results as
the volunteer was assumed to have had the DTaP vaccine within
the last 5 years. Each volunteer was offered a $50 gift certificate
to CVS Pharmacy upon completion of the study. All eligible
participants were enrolled and signed the consent form approved
by the local Institutional Review Board. This trial is registered at
ClinicalTrials.gov as NCT03557463.
Human Samples
Peripheral blood samples were collected at the time of enrollment
(week 0) and serum was stored at −80◦C until subsequent
analysis. Participants were then randomized into two groups and
provided with equal concentration and quantity of either dairy
or soy supplement provided in powdered form in coded, single-
serving bags. Both participants and researchers were blinded to
the type of protein received. Participants were asked to consume
two servings of protein powder (6 grams/packet) with 4 ounces
of water or applesauce twice per day, with meals, for a total of 8
weeks. At week 4, participants were vaccinated withDTaP vaccine
(Sanofi Pasteur Inc., Swiftwater PA). A 0.5-mL dose of Adacel R© is
formulated to contain 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria
toxoid, 8 µg of inactivated PT, 8 µg of FHA, and 2.5 µg of
pertactin (69 kiloDalton outer membrane protein). Each 0.5-mL
dose contains aluminum hydroxide as adjuvant (not more than
0.39mg aluminum by assay), 4.5mg of sodium chloride,≤100µg
of residual formaldehyde, and≤100µg of polysorbate 80 (Tween
80). A second blood draw was obtained 4 weeks after vaccination
(week 8) and serumcollected for DTaP antibody analysis. The
design and participant progression through the study is presented
in Figure 1.
Protein Supplements
Low isoflavone soy protein was purchased commercially from
ADM, Minneapolis, USA. Tamarack Biotics, LLC provided a
UV-C treated raw milk protein supplement, TruActiv MPC
85. Briefly, raw milk is exposed to UV-C light in a turbulent
flow system at a rate of 4,000 L/hour with an applied UV-C
dose of 2,000 J/L. After UV-C treatment, the milk was dried
using a high volume air dryer with maximum temperature
exposure of 42◦F (6◦C) for 2min, packaged into 25 kg aluminum
storage bags with oxygen scavenger and stored frozen. Prior to
participant consumption, the batch of UV-C treated milk powder
was analyzed by third-party National Food Laboratory, LLC per
the following minimum guidelines, as stipulated by the FDA
Pasteurized Milk Ordinance (19).
Table 1 contains the analysis of one dose of the dairy protein
source present in one serving of the powdered supplement
consumed by participants. Each participant was required to
consume a total of 112 servings for the 8-week duration of the
study. A 4-week supply was provided at baseline (week 0) and at
the time of vaccine administration (week 4). Six grams of either
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FIGURE 1 | Flowchart illustration represents randomization of participants and
progress through the phases of the trial.
TABLE 1 | Product Analysis of TruActiv MPC85.
Analytical Test Results Specifications Test Method
Standard plate 8,500 CFU/g <10,000 CFU/g USP <2021>
Coliform count <3 MPN/g <2,500 MPN/g AOAC 966.24
Escherichia coli <3 MPN/g <3 MPN/g AOAC 988.19
Staphylococcus Absent Per 10 g Absent Per 10 g USP <2002>
Salmonella Absent Per 25 g Absent Per 25 g USP <2002>
Yeast <100 CFU/g <5,000 CFU/g USP <2002>
Mold <100 CFU/g <5,000 CFU/g USP <2002>
Listeria Negative Per 25 g Negative Per 25 g FDA BAM
Moisture 5.37 Wt. % <7 Wt. % AOAC 930.15
the dairy or soy protein and 2 grams of a flavoring ingredient
(vanilla flavored powder) were measured into single serving bags.
Bags were coded based on protein type and both participants and
researchers were blinded to the underlying code. All subjects were
instructed to prepare and consume the supplement with water or
added to applesauce, twice a day in addition to their normal diet.
Participants were explicitly advised not to use the supplement as
a substitute for any part of their normal diet. Compliance was
evaluated by the assisted living facility nursing staff throughout
the study by collection of sample containers.
Measurement of Antibody Response
Serum samples were obtained at week 0 and week 8,
stored at −80◦ C and analyzed for concentration of DTaP-
specific antibodies using Enzyme Immunoassay (EIA) (Quest
Diagnostics Infectious Disease, Inc., San Juan Capistrano, CA).
Type-specific antibody concentration post-vaccine ([Ab8]Tx)
minus the concentration pre-vaccine ([Ab0]Tx) was used to
TABLE 2 | Demographic and health characteristics of two study groups.
Dairy protein (N = 10) Soy protein (N = 11)
Age (years)* 72.30 ± 8.04 74.36 ± 10.49
Male (N) 5 4
Female (N) 6 6
Body Mass Index (kg/m2)* 28.67 ± 4.25 28.47 ± 3.00
Exercise (days/week)* 2.21 ± 2.55 2.86 ± 2.56
*Continuous variables are expressed as mean± SEM. Values are not significantly different
between groups.
determine the change in antibody concentration for a given
serotype (D[Ab]Tx).
Results were expressed quantitatively (µg/mL) based on the
obtained standard curves. Samples included all individuals who
completed the supplementation trial with the dairy (N = 10)
and soy protein (N = 11). A minimal four-fold increase between
pre-immunization and post-immunization sera is considered a
normal response to Tetanus toxoid. Levels >0.50 IU/mL are
generally considered protective, whereas levels between 0.05 and
0.49 IU/mL are indeterminate for the presence of protective
antibody and may indicate a need for further immunization to
Tetanus toxoid.
Statistical Analysis
Data between different groups were compared using the
nonparametric Mann–Whitney U-test (continuous variables) or
chi square test (categorical variables). Nonparametric tests were
used due to the small sample size. Mean and standard error
of the mean (SEM) are reported for the change in antibody
response for each volunteer. The average change in antibody
concentration within the dairy and soy groups were compared.
For each antibody, data between groups were compared using
nonparametric t-tests for continuous variable and chi square test
for categorical variables. All analyses were two-tailed and p <
0.05 considered statistically significant. Analyses were conducted
in SPSS (Version 24) for Mac OSX.
RESULTS
A total of 21 participants aged 63-94 years (average age
73.4 ± 9.2) were included in final analyses (Table 2). Of
38 participants originally enrolled, 8 dropped out (2 due to
intestinal distress, 3 did not like the taste, 2 had low compliance,
and 1 for unknown reasons). Nine volunteers were excluded
who had a baseline Tetanus antibody level greater than 3
IU/mL and so assumed to have received DTaP vaccine within
5 years.
Tetanus antibody levels were not different between
supplementation groups at week 0. Both supplementation
groups exhibited an increase in Tetanus antibody levels at 4
weeks post vaccine. Nonparametric t-tests (Mann–Whitney U)
revealed a significantly greater increase in Tetanus antibody
levels in the group that received the UV-C treated dairy protein
versus the soy protein supplement (11.20 ± 1.05 versus 7.10
± 1.34 IU/mL; p = 0.029), see Table 3. Response to diphtheria
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TABLE 3 | Change in Tetanus antibody concentration (IU/mL) in two elderly
groups supplemented with the dairy and soy protein.
Soy Tetanus Antibodies (IU/mL)
Week 0 Week 8 Week 8 - Week 0
1 0.65 3.60 2.95
2 2.73 6.26 3.53
3 0.64 7.73 7.09
4 0.85 5.14 4.29
5 0.69 16.00 15.31
6 0.80 12.98 12.18
7 2.31 7.66 5.35
8 2.37 15.70 13.33
9 1.20 4.59 3.39
10 1.09 4.75 3.66
11 1.35 8.32 6.97
Mean ± SEM 1.33 ± 0.23 8.43 ± 1.35** 7.10 ± 1.34*
Dairy Week 0 Week 8 Week 8 - Week 0
1 1.01 6.58 5.57
2 0.91 11.90 10.99
3 0.30 11.90 11.60
4 1.54 10.70 9.16
5 0.88 8.84 7.96
6 1.22 16.00 14.78
7 0.59 9.62 9.03
8 1.02 16.00 14.98
9 0.73 13.00 12.27
10 0.38 16.00 15.62
Mean ± SEM 0.86 ± 0.12 12.05 ± 1.03** 11.20 ± 1.05*
*Average change in antibody levels (week 8 - week 0) is significantly different between
groups (p = 0.029).
**Average post-vaccine antibody level is higher at week 8 in dairy group compared to soy
group (p = 0.034).
A multiple linear regression was conducted to explore the relationship between antibody
level changes and volunteer age and sex and no effects were seen.
and pertussis (PT and FHA) vaccines were also greater in
the dairy protein group, but differences were not statistically
significant.
DISCUSSION
The results of this randomized, double-blind pilot study suggest
that consuming a nutritional supplementation from UV-C
treated unheated dairy protein may have increased benefits
for stimulating the immune system in senior citizens. For
generalizability, these preliminary results should be replicated in
a larger population. Future research should also include a group
consuming heat-treated milk to determine whether the benefits
are associated with the absence of heating in the UV-C treated
milk protein.
Immunosenescence is a significant concern in aging
populations accounting for higher incidence of infection
and poor vaccine response (1, 2). The aging immune system
undergoes changes that impair adaptive immune response
(20). Diet-based approaches have potential to boost immune
stimulation and counteract immunosenescence. A significant
portion of the immune system is located in the mucosal lining
of the digestive tract. Our results suggest that unheated dairy
protein was associated with enhanced immune response to
the tetanus vaccine. Our results are in agreement with (9)
who demonstrated an enhanced response to a Streptococcus
pneumoniae vaccine among elderly supplemented with whey
protein compared to those who were supplemented with soy
protein.
Because in the Freeman study it was demonstrated that
heated whey proteins already benefit immunological response,
we can reasonably anticipate that the difference between a
heated and unheated milk group would be smaller. Because
the present study was a small pilot, it would not likely carry
sufficient statistical power to detect a difference between heated
and unheated milk proteins. Rather, heated milk proteins
should be included in a larger follow-up study that allows for
sufficient power. Very few studies have examined the differences
between unheated and heated milk proteins, although one
group demonstrated increased immune system activation in a
mouse model fed raw milk protein compared to a heated milk
protein (21).
Brick (22) showed that with increasing heat intensity,
more immunologically active milk proteins become damaged.
It is reasonable to hypothesize that the effect seen in the
mouse study by (21) was caused by to damage to the
immunologically active proteins in the heated milk protein, as
milk protein is the most heat sensitive fraction. Proteomics
analyses carried out similar to (22) show that the typical heat
damage can be prevented by applying UV-C to milk (data
not shown). This indicates that the effect of heating shown
by Brick et al. (22) may extend to powdered milk protein
products.
These hypotheses are further supported by studies that have
shown raw bovine milk to be immunologically supportive,
aiding in the prevention of allergy, asthma and respiratory
illness in children (23–26). Wyss et al. (27) reported raw
milk consumption in childhood to be associated with higher
pulmonary function that lasts into older adulthood. Until
now, the risks of raw milk including food borne illness and
pathogens have far outweighed the benefits (28). Non-thermal
UV-C radiation techniques offer a solution by eliminating
illness causing microorganisms in a capacity similar to thermal
processing techniques. To our knowledge this is the first
study to examine the impact of UV treated milk protein on
immune response in any population. There have been no studies
to show immune enhancing benefits over pasteurized dairy
sources.
Because this was a small pilot study, results are limited
in generalizability and larger clinical studies are needed to
confirm immune supportive effects of dairy protein derived
from UV-C treated raw milk. In addition to small sample
size, this study has several other limitations. Although the
age range of elderly volunteers varied widely (60–94 years)
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it was not possible to stratify by age in the analyses due to
a limited power but the authors recommend follow-up trials
incorporate age stratification to determine differences between
age groups. The nutritional status of participants was not
assessed due to lack of resources available in this preliminary
study. However, due to the confounding relationship with
immune function, nutrition status should be accounted for
in this population (9). Although it is worthwhile to note
that participants were likely consuming somewhat similar diets
because they consumed food from the same assisted living
center.
CONCLUSION
In conclusion, this pilot study demonstrated a potential immune
stimulating effect of UV-C treated raw dairy protein in vaccine
response among elderly participants. These early findings suggest
there may be additional benefits of UV-C treated raw dairy
proteins for immunosenescence, but warrant further study in
elderly and other populations that can benefit from immune
system stimulation.
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